First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Amit Khot(The Royal Melbourne Hospital), Simon J. Harrison(Peter MacCallum Cancer Centre), Richard B. Pearson(The University of Melbourne), Andrew Fellowes(Peter MacCallum Cancer Centre), Elaine Sanij(The University of Melbourne), Ross D. Hannan(University of Canberra), Natalie Brajanovski(Peter MacCallum Cancer Centre), Karen E. Sheppard(The University of Melbourne), Ella R. Thompson(Peter MacCallum Cancer Centre), Grant A. McArthur(The University of Melbourne), Piers Blombery(The University of Melbourne), Donald P. Cameron(Karolinska Institutet), John Soong(Hwa Hsia University of Technology), Emma Link(Peter MacCallum Cancer Centre), Nadine Hein(Acton Institute), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), John K. C. Lim(Hwa Hsia University of Technology), Gretchen Poortinga(Peter MacCallum Cancer Centre)
Cited by 201
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k